Slate Run Pharmaceuticals recalls Eptifibatide Injection
FDA Class III
FDA classified this recall as Class III: the product is unlikely to cause health problems but breaks the agency's rules (a labeling mistake, for example).
- Hazard
- Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for weight-adjusted infusion.
- Products
-
- Eptifibatide Injection
- Company
- Slate Run Pharmaceuticals
- Where it was sold
-
Nationwide within the USA.
Nationwide
- Units affected
- N/A
- About this recall
- Eptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus dosing, 1x100 mL Single-dose Vial, For Intravenous Use Only, Rx Only, Manufactured by: Hainan Poly Pharm. Co., Ltd., Guilinyang Economic Development Area, Haikou, Hainan Province, China 571127; Distributed by: Slate Run Pharmaceuticals, LLC, Columbus, Ohio 43215. NDC Slate Run Carton Label: 70436-027-80; NDC ProRx Carton Label: 70436-163-80